Psychiatric News (1/23) reports, “When it comes to the risk of metabolic side effects, not all antipsychotics are equal,” investigators concluded in a 137-study network meta-analysis encompassing “35,007 participants who had taken 31 different antipsychotics (both oral and injectable) that are available in the United States and/or Europe.” After comparing “the effects of these medications on body weight as well as fasting glucose, cholesterol, and triglyceride levels,” the study team found that “patients with schizophrenia who took chlorpromazine or clozapine for more than 13 weeks experienced the most weight gain on average compared with those taking placebo.” The findings were published online Jan. 14 in the journal World Psychiatry.
Related Links:
— “Metabolic Side Effects of Antipsychotics Vary, Meta-Analysis Finds, Psychiatric News, January 23, 2023